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Background: Autologous stem cell transplantation (ASCT) is the standard treatment for patients 
with relapsed diffuse large B-cell lymphoma (DLBCL) or transformed indolent lymphoma (TIL). 
The treatment is mainly considered for younger patients still available for the work market. In 
this study, social outcomes after ASCT in terms of return to work (RTW) are described.
Patients and methods: Information from national administrative registers was combined with 
clinical information on patients, who received ASCT for relapse of DLBCL or TIL between 2000 
and 2012. A total of 164 patients were followed until RTW, disability or old-age pension, death, 
or December 31, 2015, whichever came first. A total of 205 patients were followed with disability 
pension as the event of interest. Cox models were used to determine cause-specific hazards. 
Results: During follow-up, 82 (50%) patients returned to work. The rate of returning to work 
in the first year following ASCT was decreased for patients being on sick leave at the time of 
relapse (hazard ratio [HR] 0.3 [0.2;0.5]) and increased for patients aged ≥55 years (HR 1.9 
[1.1;3.3]). In all, 56 (27%) patients were granted disability pension. Being on sick leave at the 
time of relapse was positively associated with receiving a disability pension in the first 2 years 
after ASCT (HR 3.7 [1.8;7.7]). 
Conclusion: Patients on sick leave at the time of relapse have a poorer prognosis regarding 
RTW and have a higher rate of disability pension. Furthermore, patients >55 are more likely 
to RTW compared to younger patients. These results indicate an unmet need for focused social 
rehabilitation. 
Keywords: social outcomes, chemotherapy, relapse treatment, disability pension, epidemiology
Introduction
All cancer patients are at risk of developing health impairments that result in a decrease 
in their ability to work.1,2 This may lead to a loss of identity and affect self-esteem, and 
it may also, even in tax-funded, free-of-charge health systems, give rise to financial 
concerns.3,4 Social involvement and income levels improve the quality of life of can-
cer survivors,5–7 and studies have shown that patients often regard returning to work 
as indicative of complete recovery and regained normality.8,9 Previous studies have 
found that cancer patients have impaired work market affiliation10,11 and a higher risk 
of taking a disability pension in the years after diagnosis.12
Denmark has a wide-ranging tax-financed welfare system and a high level of social 
security covering all citizens. If a person is not able to work due to sickness, the state 
is obligated to support the individual financially through welfare benefits, such as sick 
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leave benefits. If a person is not able to work due to permanent 
disability, the person can receive a disability pension, and 
hence be financially compensated, although not equivalent to 
a full salary. Since the ability to work is positively associated 
with quality of life, there might be a negative impact of taking 
a disability pension on the person’s social function and self-
esteem.12 How receiving a disability pension affects quality 
of life has been evaluated in a study among 1143 persons 
followed for 1 year after the start of the disability pension. 
It was found that quality of life increased during the first 
year, but persons who were re-employed had an even higher 
quality of life than those who stayed retired.13 However, in 
Denmark, it is a rare event to become re-employed on a dis-
ability pension.
High-dose chemotherapy with autologous stem cell trans-
plantation (ASCT) is the standard therapy for patients with 
primary refractory or relapsed diffuse large B-cell lymphoma 
(DLBCL), as well as for patients with transformed indolent 
lymphoma (TIL).14 This potentially curative treatment is 
toxic with many side effects and is mostly considered for 
younger patients without major comorbidities.15 This young 
patient group is still eligible for the work market. Quality 
of life after ASCT has been shown to be associated with 
employment status and to be decreased compared to the 
general population.16–18
The aim of this study was to describe the rate of return 
to work (RTW) and of taking a disability pension in patients 
receiving ASCT as relapse treatment, and to evaluate the 
influence of comorbidity, socioeconomic, and clinical factors 
on these social outcomes. If patients at risk of not returning 
to work could be identified, early targeted interventions 
could be initiated for those at the highest risk of developing 
work-related problems.
Patients and methods 
Patients
A population-based nationwide cohort study using the clinical 
Danish National Lymphoma Registry (LYFO) was conducted 
to identify patients with relapsed B-cell lymphoma in Denmark 
in the period 2000–2012, who underwent ASCT. The LYFO 
includes data on all lymphoma patients who have been treated 
at hematological departments in Denmark since 2000.19,20 Fur-
thermore, medical records were reviewed for clinical, patho-
logical, and treatment information. Patients with DLBCL and 
TIL aged ≥18 at the time of diagnosis were included. Patients 
undergoing ASCT as part of first-line treatment, patients with 
primary or secondary central nervous system lymphomas, and 
patients with Richter transformation were excluded.
All Danish residents are assigned a unique Central Person 
Registry (CPR) number at birth or at the time of commenc-
ing residence in Denmark. Linkage to The Civil Registration 
System tracks changes in the vital status and residential 
area daily, and the CPR number allows linkage between 
national administrative registries and clinical databases in 
Denmark.21,22
Covariates
Information on clinical factors was obtained from the indi-
vidual medical records. Disease-specific variables such as 
lymphoma subtype, primary refractory disease, and inter-
national prognostic index (IPI) were analyzed in order to 
consider disease burden. To evaluate the treatment toxicity, 
information on days of admission during salvage therapy 
and performance status on the day of admission for high-
dose therapy were obtained. In addition, the patient-specific 
variables such as sex and age were also analyzed, with an 
age cut-off of 55 years.
Comorbidity
Information on comorbidity was obtained from the Danish 
National Patient Registry (DNPR), which includes informa-
tion on all hospitalizations since 1978 and, from 1995, also 
on outpatient visits.23 To estimate the burden of comorbidity, 
all somatic diagnoses other than lymphoma were retrieved 
from the DNPR. Comorbidity was measured as the number of 
comorbidities, using the 19 disorders specified in the Charlson 
comorbidity index, grouped into no comorbidities, one, and 
two or more. In the RTW analysis, comorbidity was grouped 
into no comorbidities and one or more due to small numbers.
Socioeconomic factors
Information on socioeconomic factors was obtained via data 
linkage to various population-based administrative registers 
operated by Statistics Denmark that contain annually updated 
data on a broad range of socioeconomic factors.24,25 Informa-
tion on the highest attained educational level by October 1 
the year before relapse was obtained, and this was catego-
rized as short (mandatory school, 7 or 9 years depending on 
the year of birth), medium (youth or vocational education, 
10–12 years of education), and higher education (>12 years 
of education). Disposable income the year before relapse 
was grouped into quintiles based on the population of the 
same sex and birth cohort, calculated per person after taxa-
tion and interest. Disposable income was categorized as low 
(first quintile), medium (second to third quintile), and high 
(fourth to fifth quintile). Information on cohabitation status 
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was obtained by January 1 of the year of relapse and was 
defined as living alone or with an adult partner. 
Work market affiliation
Information on welfare benefits and work market affiliation 
was obtained from the Danish Register for Evaluation of Mar-
ginalization (DREAM). DREAM includes data on all Danish 
residents who have received any social transfer payments or 
welfare benefits since 1991. Each person is registered weekly, 
with a code representing the type of social transfer payment 
received.26,27 Patients were included in the RTW analysis, 
if they were registered with sick leave at the time of stem 
cell reinfusion. RTW was defined as the first period of four 
consecutive weeks without receiving any welfare benefits.26,28 
Patients were included in the disability pension analysis, if 
they were not registered with a disability or old-age pension 
at the time of relapse. Information on disability pension 
was available from DREAM. Permanent withdrawal from 
the work market was defined as taking a disability pension 
(including wage-diminished employment, so-called flex jobs) 
and old-age pension or age >65 years.
Statistical analysis
Patient baseline characteristics were analyzed descriptively 
and compared by chi-square test. Patients were followed 
from the day of stem cell reinfusion until an event of inter-
est (disability pension or RTW), death, old-age pension or 
age 65 years, or 31 December 2015, whichever came first. 
Cumulative incidences were estimated for each event type. 
Cox proportional hazard models were used to determine 
cause-specific hazards for RTW within the first year after 
ASCT and disability pension within the first 2 years account-
ing for competing risks (death, old-age pension, or age 65 
years); all of the variables listed in Tables 1 and 2 were 
tested one at a time. The proportional hazards assumption 
was tested and fulfilled for all models in the disability pen-
sion analysis. For the RTW analysis on sex and performance 
status, hazards were not proportional, but graphical control 
showed no crossing of curves. Due to multiple testing on 
a small patient cohort, the p-values were adjusted by the 
Bonferroni method. Factors that remained significant were 
included in a fully adjusted model, taking into account age, 
sex, and period. All analyses were conducted using R 3.2.2, 
using packages “Surv” and “cmprsk.”29,30
Ethics
The study was approved by the Danish Data Protection 
Agency (30-1251) and the Danish Patient Safety Authority 
(3-3013-574/1). The study is register based, and according to 
approval from the Danish Patient Safety Authority, informed 
consent from participants was not required.
Results
A total of 369 patients, who received ASCT for primary 
refractory or relapsed DLBCL or TIL in Denmark in the 
period 2000–2012, were identified. The median age was 
58 years (range 22–73), and 60% were male. At the time of 
stem cell reinfusion, 164 patients were on sick leave, a total 
of 163 had permanently withdrawn from the work market 
(61 patients received some kind of disability pension and 
102 patients obtained old-age pension), and 41 patients did 
not receive any welfare benefits (Figure 1). 
Return to work analysis
For the 164 patients included in the RTW analysis, the median 
age was 54 years (range 25–65) (Table 1), 78 (48%) had TIL, 
86 (52%) had DLBCL, and 54 patients (33%) had primary 
refractory disease. At time of relapse, 50 patients (31%) had a 
low IPI score, 61 patients (37%) had an intermediate or high 
IPI score, and IPI score was missing for the remaining patients. 
During salvage therapy, 31 patients (19%) had prolonged 
admission >28 days, and 40 patients (24%) had a perfor-
mance status above 0 at the time of ASCT (Table 1). A total 
of 153 patients received etoposide, cytarabine, and melphalan 
(BCNU) as conditioning regimens, and 11 received TBI.
Median time to RTW was 420 days, ranging from 13 
to 914 days. Sixty (37%) patients returned to work within 
the first year after ASCT, 16 (10%) received disability 
pension, and 7 (4%) were retired. A total of 49 (30%) 
were still on sick leave after the first year, and 32 (20%) 
died within the first year without returning to work. After 
Bonferroni adjustment, only sick leave at the time of 
relapse maintained significance (p<0.001) (Table 1). In 
a fully adjusted model taking into account sex, period, 
and age, sick leave at the time of relapse was associated 
with a significantly poorer RTW prognosis with a hazard 
ratio (HR) of 0.31 (0.2;0.6). Age ≥55 years was associated 
with a better RTW prognosis with a HR of 1.90 (1.1;3.3), 
although this diminished over time (Figure 2). Of the 48 
patients still on sick leave 1 year after ASCT, five (10%) 
had developed a subsequent relapse. Of the 86 patients 
under the age of 55, 59 patients were on sick leave at time 
of relapse, and 27 patients were not on sick leave. Of the 
patients on sick leave, 12 (20%) returned to work within 
the first year after ASCT, whereas 12 (44%) of the patients 
not on sick leave returned to work within the first year. For 
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the 78 patients aged ≥55, 42 patients were on sick leave at 
time of relapse, and 10 (22%) returned to work within the 
first year after ASCT, and 26 (72%) of the 36 patients not 
on sick leave had returned to work.
Disability pension analysis
A total of 205 patients were eligible for the analysis on 
disability pension (Figure 1). The median age was 54 years 
(range 25–66), and time to receiving a disability pension 
Table 1 Baseline characteristics and HRs (with accompanying 95% CIs) for returning to work within the first year after ASCT for the 
164 patients with diffuse large B-cell lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included in the analysis 
on return to work
Variables N (%) Events HR (95% CI) p-value
Total 164 60
Age    0.05
 <55 years 86 (52) 13 1.00(ref)
 ≥55 years 78 (48) 47 1.82(1.0;3.4)
Sex     0.5
 Male 104 (63) 38 1.00(ref)
 Female 60 (37) 22 0.83(0.5;1.4)
Period 0.6
 2000–2003 41 (25) 12 1.00(ref)
 2004–2007 66 (40) 42 1.44(0.7;2.9)
 2008–2012 57 (35) 22 1.23(0.6;2.5)
Subtype 0.2
 DLBCL 86 (52) 26 1.00(ref)
 TIL 78 (48) 34 1.39(0.8;2.3)
IPI score at relapse    0.9
 Low 50 (31) 17 1.00(ref)
 LI/HI/high 61 (37) 21 1.02(0.5;1.9)
Antidepressants or anxiolytics 0.3
 No 116 (70) 44 1.00(ref)
 Yes 48 (22) 16 0.72(0.4;1.3)
Comorbidities    0.6
 None 118 (72) 42 1.00(ref)
 One or more 46 (28) 18 1.14(0.7;2.0)
Disposable income    0.2
 Low 20 (12) 5 1.00(ref)
 Medium 71 (43) 22 1.05(0.4;2.8)
 High 73 (45) 33 1.69(0.7;4.3)
Educational level    0.3
 Low 43 (26) 19 1.00(ref)
 Medium 83 (51) 30 0.79(0.4;1.4)
 High 36 (22) 10 0.54(0.3;1.2)
Welfare benefit at the time of relapse   <0.001*
 None 63 (38) 38 1.00(ref)
 Sick leave 101 (62) 22 0.30(0.2;0.5)
Primary refractory disease    0.05
 No 110 (67) 46 1.00(ref)
 Yes 54 (33) 14 0.54(0.3;1.00)
Change during salvage treatment    0.2
 No 113 (69) // 1.00(ref)
 Yes 19 (12) // 0.47(0.2;1.5)
Days of admission during salvage   0.05
 <14 82 (50) 35 1.00(ref)
 14–28 44 (27) 16 0.82(0.5;1.5)
 >28 31 (19) 5 0.26(0.1;0.8)
PS at day 7    0.5
 0 109 (67) 43 1.00(ref)
 >0 40 (24) 9 0.78(0.4;1.6)
Notes: *p-values significant after Bonferroni adjustment; //, ≤5 events; Numbers may not add up to 164 due to missing data.
Abbreviations: ASCT, autologous stem cell transplantation; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HI, high intermediate; HRs, hazard ratios; IPI 
score, international prognostic index score; LI, low-intermediate; PS, performance status; ref, reference; TIL, transformed indolent lymphoma.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 2
6-
O
ct
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
325
Work market affiliation after autologous stem cell transplantation
ranged from 42 days to 2911 days. Among the 205 patients 
included, a total of 56 (27%) received a disability pension 
in the study period. Of the 205 patients included, 99 (48%) 
had TIL, 70 patients (34%) had primary refractory disease, 
53 patients (26%) had a low IPI score at time of relapse, and 
77 (38%) had an intermediate or high IPI score. A total of 
40 patients (20%) had prolonged admission during salvage 
therapy (>28 days), and 40 (20%) had a performance status 
>0 at the time of ASCT (Table 2).
Within the first 2 years after ASCT, 37 (18%) patients 
were granted a disability pension, 16 (8%) were retired, 100 
(49%) were still available for work, and 52 (25%) had died. 
After Bonferroni adjustment, the period and sick leave at the 
time of relapse were significantly associated with outcome 
(Table 2). In the fully adjusted model, age, sex, and period 
were taken into account. Sick leave at the time of relapse was 
associated with a worse disability pension prognosis (HR 3.72 
[1.8;7.7]). Fewer were granted a disability pension in the later 
part of the study, the HR decreasing from 0.47 (0.2;1.0) in the 
period 2000–2003 to 0.24 (0.1;0.6) in 2004–2007 compared 
to 2008–2012. Of the 37 patients, who received a disability 
pension within the first 2 years after ASCT, 11 (30%) had 
developed a subsequent relapse. Of the 103 patients <55, 59 
patients were on sick leave at time of relapse, and of them 
15 (25%) received disability pension within the first 2 years 
after ASCT. Of the 44 patients not on sick leave at the time 
of relapse, 6 (14%) patients received disability pension. For 
the 102 patients aged ≥55, 42 patients were on sick leave at 
the time of relapse, of whom 11 (26%) received disability 
pension, and 5 (8%) of the 60 patients not on sick leave 
received disability pension.
Discussion
In this nationwide cohort study, it was found that being 
on sick leave at the time of relapse was associated with an 
impaired work market affiliation in the years after ASCT. This 
was true for both RTW and disability pension. Furthermore, 
age >55 years was positively associated with RTW.
The findings of this study are consistent with a Norwegian 
register study matching 2008 cancer survivors with a cancer-
free control group. In the Norwegian study, they found that 
sick leave in the year before the cancer diagnosis predicted 
sick leave 5 years after.10 In a Danish population-based study 
among 3194 patients with hematological malignancies, 
Horsboel et al found that sick leave in the second year before 
diagnosis was positively associated with the risk of taking a 
disability pension.2 
A study on RTW prognosis included 1741 patients with 
hematological malignancies <55 years. They found younger 
age to be associated with an improved RTW rate.28 A recent 
Norwegian cross-sectional study on 312 long-term lym-
phoma survivors treated with ASCT between 1987 and 2008 
showed that older age was associated with a higher risk of 
having a not-employed status (odds ratio 1.04 [1.0;1.1]).18 
In the Norwegian study, the not-employed status covered 
sick leave, disability pension, and old-age pension. Since 
they included old-age pension as not employed, it is not 
surprising that older age is associated with higher risk of 
being not employed. Here, it was found found that an age 
≥55 years was associated with an improved RTW prognosis 
within the first year after undergoing ASCT. One reason 
might be that for patients ≥55 years, the risk of unemploy-
ment after a longer period of sick leave might be higher, 
motivating a faster RTW. Furthermore, older patients may 
have a more established work life and a higher influence 
on the work tasks when returning to work, thereby making 
it possible to work fewer hours or having flexible working 
hours. Both the Danish and the Norwegian studies included 
Figure 1 Flowchart of the study population. Patients with diffuse large B-cell 
lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included 
in the analyses on return to work and disability pension.
Abbreviations: ASCT, autologous stem cell transplantation; RTW, return to work.
ASCT cohort
N=369
No benefits
N=41
Sick leave benefit
N=164
RTW cohort
N=164
Disability
pension cohort
N=205
Permanent
withdrawal
N=163
Figure 2 Cumulative incidence curves for return to work within the first five 
years following ASCT for the 164 patients with diffuse large B-cell lymphoma or 
transformed indolent lymphoma in Denmark in 2000–2012 included in the return to 
work analysis, stratified on age.
Abbreviation: RTW, return to work.
Days posttransplant
0
0.0
0.4
0.8
RTW (age <55 years)
RTW (age ≥55 years)
500 1000
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a more heterogeneous patient group, whereas, in the present 
study, only lymphoma patients receiving ASCT as relapse 
treatment were included. Therefore, the patient population 
in this study is older. Furthermore, the follow-up in this 
analysis is long, and, due to the historical cohort design, the 
authors were able to study cause-specific hazards for RTW, 
Table 2 Baseline characteristics and HRs (with accompanying 95% 95% CIs) for taking disability pension within the first 2 years after 
ASCT for the 205 patients with diffuse large B-cell lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included 
in the analysis on disability pension^
Variables N (%) Events HR (95% CI) p-value
Total 205 37
Age    0.6
 <55 years 103 (50) 21 1.00 (ref)
 ≥55 years 102 (50) 16 0.84 (0.4;1.6)
Sex    1.00
 Male 130 (63) 23 1.00 (ref)
 Female 75 (37) 14 0.99 (0.5;1.9)
Period 0.01
 2000–2003 54 (26) 17 1.00 (ref)
 2004–2007 80 (39) 13 0.52 (0.3;1.1)
 2008–2012 71 (35) 7 0.27 (0.1;0.7)
Subtype 0.8
 DLBCL 106 (52) 17 1.00 (ref)
 TIL 99 (48) 20 1.02 (0.5;2.0)
IPI score at relapse    0.2
 Low 53 (26) 14 1.00 (ref)
 LI/HI/high 77 (38) 12 0.61 (0.3;1.3)
Antidepressants or anxiolytics 0.9
 No 140 (68) 25 1.00 (ref)
 Yes 65 (32) 12 1.03 (0.5;2.0)
Comorbidities    0.01
 None 148 (72) // 1.00 (ref)
 One 44 (22) // 0.46 (0.2;1.3)
 Two or more 13 (6) // 2.80 (1.2;6.8)
Disposable income    0.01
 Low 25 (12) 7 1.00 (ref)
 Medium 80 (39) 20 0.72 (0.3;1.7)
 High 97 (47) 10 0.26 (0.1;0.7)
Educational level    0.5
 Low 43 (21) 10 1.00 (ref)
 Medium 100 (49) 17 1.01 (0.5;2.3)
 High 55 (27) 9 1.59 (0.7;3.9)
Welfare benefit at the time of relapse   <0.001*
 None 104 (51) 11 1.00 (ref)
 Sick leave 101 (49) 26 3.37 (1.7;6.8)
Primary refractory disease   0.9
 Yes 70 (34) 26 1.00 (ref)
 No 135 (66) 11 0.96 (0.5;1.9)
Change during salvage    0.1
 No 139 (68) 24 1.00 (ref)
 Yes 24 (12) 6 2.06 (0.8;5.0)
Days of admission during salvage   0.1
 <14 96 (47) 13 1.00 (ref)
 14–28 57 (28) 12 1.79 (0.8;3.9)
 >28 40 (20) 10 2.48 (1.1;5.7)
PS at day 7    0.02
 0 135 (66) 25 1.00 (ref)
 >0 47 (23) 12 2.27 (1.1;4.5) 0.02
Notes: *p-values significant after Bonferroni adjustment; //, ≤5 events; ^, numbers may not add up to 205 due to missing data.
Abbreviations: ASCT, autologous stem cell transplantation; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HI, high intermediate; HRs, hazard ratios; IPI 
score, international prognostic index score; LI, low-intermediate; PS, performance status; ref, reference; TIL, transformed indolent lymphoma.
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considering disability and old-age pension as competing 
events. The risk of having to take a disability pension is not 
only associated with the ability to work, but also with the 
demands of the specific job. People with high-strain jobs 
(defined as high demands and low decision latitude) have 
a higher risk of receiving a disability pension.31 The same 
associations might be seen regarding RTW, but the authors 
were not able to control for this.
An association between comorbidity and RTW or receiv-
ing a disability pension was not found. This is consistent 
with the results reported by Horsboel et al, where comorbid-
ity was not found to be associated with RTW.28 In another 
study among 3194 patients with hematological malignancies, 
Horsboel et al found that comorbidity was positively associ-
ated with the risk of receiving a disability pension among 
both patients and the reference group.2 This is consistent 
with the results from a Danish study evaluating the risk of 
taking a disability pension among 44,905 cancer patients, 
where comorbidity was found to be positively associated 
with the risk of receiving a disability pension (relative risk 
[RR] 1.60 [1.55;1.65] and RR 1.55 [1.46;1.65] for women 
and men, respectively).12 The study population is small, and 
since patients with severe comorbidities are normally not 
considered for ASCT, only a few patients have comorbidities 
(n=57). The small sample size might explain why a significant 
association was not found.
In this study, both RTW and taking a disability pension 
were chosen as outcomes. Using data from DREAM, RTW 
can only be evaluated for patients on sick leave at the time 
of stem cell reinfusion, whereas disability pension can be 
evaluated for all patients not receiving a pension at the time 
of stem cell reinfusion. However, the age distribution in the 
entire cohort (N=369) shows that a large group of the patients 
were aged ≥60 years. For these patients, a disability pension 
may not be considered due to the long processing time. The 
authors chose to include all patients regardless of age due 
to the small sample size, and by accounting for competing 
events the authors have tried to minimize this bias. Further-
more, disability pension 2 years after ASCT was examined 
in order to account for the time it takes to be granted a dis-
ability pension. All possible efforts must have been made for 
a person to be able to RTW before a disability pension can 
be granted, and the time from application to final decision 
may be a lengthy process.
It has been investigated whether rehabilitation programs 
can improve RTW prognosis and quality of life, and results 
are not consistent. However, in a recent Cochrane review, 
there is moderate evidence that rehabilitation programs do 
improve RTW prognosis, whereas no difference was found 
regarding the quality of life.32 Future rehabilitation programs 
might benefit from a tailored approach,33 also considering 
social position.
Strengths and limitations
The strengths of this study include the nationwide patient 
inclusion; all relevant patients receiving ASCT in the study 
period are included. Due to the toxicity of ASCT and the 
risk of treatment-related mortality, patients undergo clinical 
evaluation before being offered the treatment. Therefore, the 
patient cohort is homogeneous. Furthermore, the exclusion 
of patients receiving ASCT as part of first-line treatment and 
patients with Richter transformation ensures that the included 
patients are comparable regarding disease status and future 
treatment. The use of population-based registries ensures 
complete follow-up. In addition, this study investigated 
the effect of a variety of variables regarding clinical status, 
disease status, treatment, comorbidity, and socioeconomic 
position; thereby, the risk of confounding was minimized. 
The fact that information on all variables was obtained from 
medical record review for each case combined with data 
from registries reduced the risk of recall and selection bias. 
Furthermore, the risk of misclassification of outcome is lim-
ited regarding disability pension, since it was assumed that 
DREAM has a 100% coverage.34 The LYFO database has a 
high coverage and all patients identified with the inclusion 
criteria from the LYFO were included. Although there might 
be a few patients not registered in the LYFO, the study group 
is believed to be representative and it is also believed that an 
eventual bias would be non-differential. Although patients 
from all centers performing ASCT in Denmark were included, 
the authors were not able to analyze data on center level due 
to Danish regulations; hence any potential differences in the 
RTW rate between the included centers in the study could 
not be ruled out.
One of the limitations is that only RTW as a parameter 
for not receiving sick leave benefits in four consecutive 
weeks was investigated. This definition may have caused 
misclassification of the outcome RTW, since patients as hav-
ing returned to work could have been misclassified, if they 
were financially supported by a partner or parents. This is 
considered to be a rare scenario, but it might have caused an 
overestimation of RTW in the study. Moreover, some patients 
may have started a new job with less demanding tasks, and 
perhaps lower salary. Therefore, RTW cannot be used as a 
measure of having obtained the same capacity to work. Fur-
thermore, the registries used are designed for administrative 
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purposes, which limited the possibility for us to obtain more 
detailed information. There is no information on self-reported 
symptoms like quality of life or physical impairments, which 
have been shown to be associated with work market affilia-
tion after ASCT.16,18 Future studies might combine register 
data with questionnaires in order to explore the association 
between these factors. Furthermore, it could be of interest to 
investigate the effect of special social rehabilitation programs 
addressed at patient groups at risk of not returning to work in 
order to improve the quality of life and social reintegration 
for patients receiving ASCT. 
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